repletion reverses hematologic symptoms within days and neurologic sequelae over weeks, reflecting differential tissue turnover
Incretin-based therapies have been associated with a body weight (BW) reduction of 5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS)
Whetham says, Instead, the legislation is complex and layered
Third-party tested, research-grade quality
Most people tolerate it well, but mild side effects may include nausea, headache, or dizziness
Longer-term use (6+ months) may create more durable improvements where enhanced dermal architecture supports ongoing collagen synthesis at rates intermediate between treatment peaks and pre-treatment baseline, potentially maintaining 40-60% of peak improvements indefinitely without continuous peptide application